Bismuth-212 radiopharmaceutical
Alternative Names: Bi-212 melanocortin alphaLatest Information Update: 16 Jul 2016
At a glance
- Originator University of Missouri System
- Developer AlphaMed
- Class Drug conjugates; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 09 May 2008 AlphaMed Inc receives a peer review grant from the National Cancer Institute for the development of the Bismuth-212 radiopharmaceutical for Malignant melanoma
- 01 Aug 2005 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections